| G-quadruplex DNA: a potential target for anti-cancer drug design H Han, LH Hurley Trends in pharmacological sciences 21 (4), 136-142, 2000 | 693 | 2000 |
| Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer CJ Whatcott, CH Diep, P Jiang, A Watanabe, J LoBello, C Sima, ... Clinical cancer research 21 (15), 3561-3568, 2015 | 689 | 2015 |
| Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl) porphine with quadruplex DNA RT Wheelhouse, D Sun, H Han, FX Han, LH Hurley Journal of the American Chemical Society 120 (13), 3261-3262, 1998 | 578 | 1998 |
| The Cationic Porphyrin TMPyP4 Down-Regulates c-MYC and Human Telomerase Reverse Transcriptase Expression and Inhibits Tumor Growth in Vivo CL Grand, H Han, RM Munoz, S Weitman, DD Von Hoff, LH Hurley, ... Molecular cancer therapeutics 1 (8), 565-573, 2002 | 544 | 2002 |
| NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA OY Fedoroff, M Salazar, H Han, VV Chemeris, SM Kerwin, LH Hurley Biochemistry 37 (36), 12367-12374, 1998 | 518 | 1998 |
| Perineural invasion and associated pain in pancreatic cancer AA Bapat, G Hostetter, DD Von Hoff, H Han Nature Reviews Cancer 11 (10), 695-707, 2011 | 506 | 2011 |
| Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray H Han, DJ Bearss, LW Browne, R Calaluce, RB Nagle, DD Von Hoff Cancer research 62 (10), 2890-2896, 2002 | 474 | 2002 |
| Selective interactions of cationic porphyrins with G-quadruplex structures H Han, DR Langley, A Rangan, LH Hurley Journal of the American Chemical Society 123 (37), 8902-8913, 2001 | 435 | 2001 |
| Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma MJ Borad, MD Champion, JB Egan, WS Liang, R Fonseca, AH Bryce, ... PLoS genetics 10 (2), e1004135, 2014 | 375 | 2014 |
| G-quadruplexes as targets for drug design LH Hurley, RT Wheelhouse, D Sun, SM Kerwin, M Salazar, OY Fedoroff, ... Pharmacology & therapeutics 85 (3), 141-158, 2000 | 307 | 2000 |
| A DNA polymerase stop assay for G-quadruplex-interactive compounds H Han, LH Hurley, M Salazar Nucleic acids research 27 (2), 537-542, 1999 | 306 | 1999 |
| Accelerated assembly of G-quadruplex structures by a small molecule H Han, CL Cliff, LH Hurley Biochemistry 38 (22), 6981-6986, 1999 | 264 | 1999 |
| Triptolide and its derivatives as cancer therapies P Noel, DD Von Hoff, AK Saluja, M Velagapudi, E Borazanci, H Han Trends in pharmacological sciences 40 (5), 327-341, 2019 | 262 | 2019 |
| Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look CJ Whatcott, H Han, RG Posner, G Hostetter, DD Von Hoff Cancer discovery 1 (4), 291-296, 2011 | 247 | 2011 |
| Targeting Aurora-2 kinase in cancer SL Warner, DJ Bearss, H Han, DD Von Hoff Molecular cancer therapeutics 2 (6), 589-595, 2003 | 233 | 2003 |
| Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions W Lin, P Noel, EH Borazanci, J Lee, A Amini, IW Han, JS Heo, ... Genome medicine 12, 1-14, 2020 | 227 | 2020 |
| Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression K Yoshida, S Toden, P Ravindranathan, H Han, A Goel Carcinogenesis 38 (10), 1036-1046, 2017 | 218 | 2017 |
| RNA interference to knock down gene expression H Han Disease gene identification: methods and protocols, 293-302, 2018 | 213 | 2018 |
| PRL phosphatases as potential molecular targets in cancer BJ Stephens, H Han, V Gokhale, DD Von Hoff Molecular cancer therapeutics 4 (11), 1653-1661, 2005 | 210 | 2005 |
| KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism AV Vaseva, DR Blake, TSK Gilbert, S Ng, G Hostetter, SH Azam, ... Cancer cell 34 (5), 807-822. e7, 2018 | 177 | 2018 |